by Raynovich Rod | Nov 23, 2016 | Biopharmaceuticals
Another clinical trial failure for an Alzheimer’s Disease in a late stage trial triggered a pre-market sell-off. Both Biogen (BIIB) -aducanumab- and Lilly (LLY)- solanezumab -drugs in development are engineered antibodies that attack beta amyloid targets in the...
by Raynovich Rod | Nov 16, 2016 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Trump Biotech Rally-Have a Balanced Portfolio Everybody who invests in biotech knows there has been a Trump biotech rally since his election as you can see from the chart and data below. Many opinions and analysis were given for the rally.Some pundits say it is...
by Raynovich Rod | Nov 9, 2016 | Biopharmaceuticals
Trump Election Win Drives Huge Biotech Rally NASDAQ up over 1% to 5248 The Trump biotech rally began at today’s opening up (IBB) 20 points to $280 then held to close up 8.9% to $285. The XBI soared 10.4% to close at $63.8 near highs of day. The cloud of drug...
by Raynovich Rod | Nov 7, 2016 | Biopharmaceuticals
Which Large Cap Biopharma Stocks Have the Best Value? But revenue growth is slowing so M&A must pick up. Drug stocks have gone through a severe correction and healthcare is one of the worse sectors YTD. Although the key indicators are still sketchy, now is the...
by Raynovich Rod | Nov 3, 2016 | Biopharmaceuticals
Rayno Life Science… Special Report #1: Hot Biotech Stocks in 2016 Biotech stocks have been in a funk for most of 2016 and then got absolutely crushed in October. The underlying causes are well-known among them bad news from bad actors like Mylan and Turing, the...
by Raynovich Rod | Oct 31, 2016 | Biopharmaceuticals
Biotech Meltdown: Numbers Don’t Mean Much Until We See New Product Growth We are almost through the earnings season and despite good results most biotech stocks tanked again today.The reason you know well by now-expectations for earnings and top line growth have...
by Raynovich Rod | Oct 26, 2016 | Biopharmaceuticals, Macro
Update-3… 10/28 9:30 am… No Relief From Earnings- Biotech Stocks Get Crushed By More Pricing Commentary on Earnings Calls Amgen (AMGN) down 11% on pipeline, revenue growth, Enbrel pricing concerns despite beat. Softer pricing environment from McKesson...
by Raynovich Rod | Oct 21, 2016 | Biopharmaceuticals, Clinical Diagnostics and Tools
CLIA Labs Offer Liquid Biopsy Tests for Cancer and Precision Medicine We attended presentations from two emerging companies developing molecular diagnostics platforms focused in cancer.Their mission is to develop cost-effective, non-invasive diagnostic assays and...
by Raynovich Rod | Oct 20, 2016 | Biopharmaceuticals, Clinical Diagnostics and Tools
Microbiomes: A New Paradigm for Drug Discovery? Focus: Drugs From Gut Bacteria You may have read a few articles about the impact of the microbiomes and their impact on diets, digestion and nutrition but now there is the potential of discovering new therapies from...
by Raynovich Rod | Oct 11, 2016 | Clinical Diagnostics and Tools
Update-1 Biotechs Sinking Again …IBB down 2.48%, ILMN down another 2% Related sequencing stocks: FMI down 1.75%, PACB flat at $8.40 Illumina (ILMN) Shares Crash on Revenue Miss Illumina (ILMN) shares crashed 25% to $139, after a warning on third quarter sales ....